The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well
as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug
Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the
amount of the neurotransmitter dopamine in the frontal cortex of the brain.